News

Cardiac amyloidosis is a condition where abnormal protein deposits build up in the heart, making it stiff and causing it to work less effectively. One common type…

− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart…

1 IntroductionSystemic light chain amyloidosis (AL) occurs due to a clonal plasma cell dyscrasia, typically with multi-system involvement and associated with a poor…

BridgeBio Pharma Inc. (BBIO), a commercial-stage biopharmaceutical company, on Monday announced new data from its Phase 3 ATTRibute-CM study of Acoramidis,…

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized yet frequently underdiagnosed cause of heart failure, particularly among older adults.…

-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM,…

Bayer has announced successful results from a Phase III clinical trial evaluating its investigational PET tracer, iodine 124 evuzamitide, designed for diagnosing…

This weekend at the European Society of Cardiology’s Heart Failure 2026 Congress in Barcelona), the first data from AstraZeneca’s (LSE: AZN) Phase III CARDIO-…

People with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) often experience eye-related complications such as eye dryness and floaters in the…

The American Heart Association launches cluster randomized trial to improve detection of ATTR cardiomyopathy within hospitals participating in Get With The…